FDA's RSABE on NTIDs in R [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2018-03-02 00:39 (2219 d 09:50 ago) – Posting: # 18492
Views: 13,362

Dear CECIF,

❝ Now, If I understand correctly this is bioequivalent because:


❝ 1. 95% CI of RSABE criterion= -0.009828289 <0


Correct.

❝ 2. Conventional ABE test: 0.9 < 0.9429483, 1.11>1.029172 (or is it also with conventional limits 0.8 and 1.25?).


As Detlew already pointed out: 80–125%. See the guidance:

Use the unscaled average bioequivalence procedure to determine BE for individual PK parameter(s). […] should pass […] also regular unscaled bioequivalence limits of 80.00-125.00%.


❝ 3. Upper 90% CI of the ratio swT/swR: 0.6842668<=2.5


Correct.

❝ In addition to this, do I still have to demonstrate conventional bioequivalence for:

❝ ❝ 1. Period 1 vs period 2 (regular bioequivalence study)

❝ ❝ 2. Period 3 vs period 4 (replicated study)

❝ ❝ 3. Pooled analysis (Average periods 1 and 3 vs average period 2 and 4)

❝ ?

❝ as they do here? https://www.accessdata.fda.gov/drugsatfda_docs/anda/99/40301_Warfarin%20Sodium_Approv.pdf


Again, as Detlew wrote: No.
BTW, I don’t see such a (strange) requirement in the ANDA of 1999 (!) you linked.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
98 visitors (0 registered, 98 guests [including 5 identified bots]).
Forum time: 10:30 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5